ID   NCC-IT
AC   CVCL_1451
SY   NCCIT
DR   BTO; BTO:0004180
DR   CLO; CLO_0007955
DR   ArrayExpress; E-MTAB-783
DR   ATCC; CRL-2073
DR   BCRC; 60314
DR   BCRJ; 0369
DR   BioSample; SAMN03471433
DR   CCLE; NCCIT_TESTIS
DR   Cell_Model_Passport; SIDM00655
DR   ChEMBL-Cells; CHEMBL3308379
DR   ChEMBL-Targets; CHEMBL1075511
DR   Cosmic; 687051
DR   Cosmic; 908441
DR   Cosmic; 1090412
DR   Cosmic; 2077186
DR   Cosmic; 2163758
DR   Cosmic-CLP; 908441
DR   DepMap; ACH-001578
DR   GEO; GSM1670159
DR   IARC_TP53; 21532
DR   NCBI_Iran; C624
DR   PharmacoDB; NCCIT_999_2019
DR   Wikidata; Q17578676
RX   PubMed=2842544;
RX   PubMed=9331070;
RX   PubMed=20164919;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=31500094;
WW   https://de.wikipedia.org/wiki/NCC-IT_(Zelllinie)
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: MAP2K4 p.Lys309Asn (c.927G>C) (PubMed=9331070).
CC   Sequence variation: Homozygous for TP53 p.Val272Cysfs*73 (c.814del) (CCLE; Cosmic-CLP).
CC   Sequence variation: Heterozygous for PTEN p.Arg173Pro (c.518G>C) (ClinVar=VCV000185195) (CCLE; Cosmic-CLP).
CC   Omics: Deep exome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=81.79%; East Asian, South=18.2%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373).
CC   Misspelling: NCC15; In PubMed=24812411 and Cosmic 2163758.
ST   Source(s): ATCC; Cosmic-CLP
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 11
ST   D16S539: 9,12
ST   D5S818: 10,13
ST   D7S820: 10
ST   TH01: 7,9
ST   TPOX: 8
ST   vWA: 14,18
DI   NCIt; C6341; Testicular embryonal carcinoma
DI   ORDO; Orphanet_289362; Non-central nervous system-localized embryonal carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Male
AG   24Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-07-20; Version: 28
//
RX   PubMed=2842544;
RA   Teshima S., Shimosato Y., Hirohashi S., Tome Y., Hayashi I.,
RA   Kanazawa H., Kakizoe T.;
RT   "Four new human germ cell tumor cell lines.";
RL   Lab. Invest. 59:328-336(1988).
//
RX   PubMed=9331070;
RA   Teng D.H.-F., Perry W.L. III, Hogan J.K., Baumgard M., Bell R.,
RA   Berry S., Davis T., Frank D., Frye C., Hattier T., Hu R.,
RA   Jammulapati S., Janecki T., Leavitt A., Mitchell J.T., Pero R.,
RA   Sexton D., Schroeder M., Su P.-H., Swedlund B., Kyriakis J.M.,
RA   Avruch J., Bartel P., Wong A.K.C., Oliphant A., Thomas A.,
RA   Skolnick M.H., Tavtigian S.V.;
RT   "Human mitogen-activated protein kinase kinase 4 as a candidate tumor
RT   suppressor.";
RL   Cancer Res. 57:4177-4182(1997).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31500094; DOI=10.3390/cancers11091316;
RA   Bakardjieva-Mihaylova V., Skvarova Kramarzova K., Slamova M.,
RA   Svaton M., Rejlova K., Zaliova M., Dobiasova A., Fiser K., Stuchly J.,
RA   Grega M., Rosova B., Zachoval R., Klezl P., Eis V., Kindlova E.,
RA   Buchler T., Trka J., Boublikova L.;
RT   "Molecular basis of cisplatin resistance in testicular germ cell
RT   tumors.";
RL   Cancers (Basel) 11:1316.1-1316.18(2019).
//